| ACC | American College of Cardiology |
| ACS | Acute Coronary Syndrome |
| AHA | American Heart Association |
| ASCVD | Atherosclerotic Cardiovascular Disease |
| BMI | Body Mass Index |
| BP | Blood Pressure |
| CAD | Coronary Artery Disease |
| CI | Confidence Interval |
| CRP | C-Reactive Protein |
| CV | Cardiovascular |
| CVD | Cardiovascular Disease |
| DASH | Dietary Approaches to Stop Hypertension |
| DM | Diabetes Mellitus |
| ESC | European Society of Cardiology |
| EVOPACS | Evolocumab for Early Reduction in LDL cholesterol levels in Patients With Acute Coronary Syndromes |
| FPP | Farnesyl Pyrophosphate |
| HDL | High-Density Lipoprotein |
| HDL-C | High-Density Lipoprotein Cholesterol |
| HMG-CoA | Hydroxymethylglutaryl-Coenzyme A |
| HR | Hazard Ratio |
| IPE | Icosapent Ethyl |
| LCBI | Lipid Core Burden Index |
| LDL | Low-Density Lipoprotein |
| LDL-C | Low-Density Lipoprotein Cholesterol |
| LLT | Lipid-Lowering Therapy |
| MACE | Major Adverse Cardiovascular Events |
| MI | Myocardial Infarction |
| NIRS | Near-Infrared Spectroscopy |
| NSTEMI | Non-ST-Elevation Myocardial Infarction |
| OCT | Optical Coherence Tomography |
| OR | Odds Ratio |
| PACT | Pravastatin in Acute Coronary Treatment |
| PCI | Percutaneous Coronary Intervention |
| PCSK9 | Proprotein Convertase Subtilisin/Kexin Type 9 |
| RCT | Randomized Controlled Trial |
| RR | Relative Risk |
| STEMI | ST-Elevation Myocardial Infarction |
| SWEDEHEART | Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies |
| TG | Triglycerides |
| UA | Unstable Angina |
| VLDL | Very-Low-Density Lipoprotein |
| hs-CRP | High-Sensitivity C-Reactive Protein |
| siRNA | Small Interfering Ribonucleic Acid |